Answers are grounded in this paper and cite their sources.
The incidence of nontuberculous mycobacteria (NTM) pulmonary disease has been increasing worldwide.However, treatment options for NTM pulmonary disease are limited by the multidrug-resistant nature of these organisms and the toxicities of antibiotics.Although linezolid (LZD) has shown its activity against NTM species in vitro studies, long-term use of LZD may be limited by its side effects.Therefore, we aimed to evaluate the efficacy and safety of LZD in the treatment of NTM pulmonary disease through a literature review.A literature search was conducted using search engines such as PubMed, Embase, and Cochrane library up to March 25, 2022.We evaluated the treatment outcomes including improvement of clinical symptoms, culture conversion, and the incidence of side effects.Of the 1,073 articles searched, 3 retrospective studies and 6 case reports met the inclusion criteria.LZD was mostly used in the treatment of Mycobacterium abscessus as a combination therapy of three or more antibiotics.Treatment success was reported in 2 retrospective studies at 67% and 81%, respectively, and in 4 out of 6 case reports.Discontinuation of LZD due to serious side effects such as myelosuppression and neuropathy was reported in 3 retrospective studies in 0%, 22%, and 39%, respectively, and in 2 out of 6 case reports.In the treatment of NTM pulmonary disease, the majority of patients on combination therapies including LZD had positive outcomes.However, many patients experienced side effects leading to discontinuation of the treatment.All NTM patients with LZD treatment should be monitored closely for the presence of serious side effects.
No takes yet. Share an insight, caveat, or question.
Park et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: